Search

Your search keyword '"Allegrini, Peter R."' showing total 174 results

Search Constraints

Start Over You searched for: Author "Allegrini, Peter R." Remove constraint Author: "Allegrini, Peter R." Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
174 results on '"Allegrini, Peter R."'

Search Results

3. Supplementary Figures S1-S4 from mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

4. Data from mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

6. Data from Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging

7. Supplementary Figure Legends 1-3 from Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging

8. Supplementary Figures 1-3 from Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging

12. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

17. Conductance catheter measurement of left ventricular volume: evidence for nonlinearity within cardiac cycle

26. Bradykinin improves postischaemic recovery in the rat heart: role of high energy phosphates, nitric oxide, and prostacyclin

27. Dual‐Modal Magnetic Resonance/Fluorescent Zinc Probes for Pancreatic β‐Cell Mass Imaging

29. Patupilone (Epothilone B) for Recurrent Glioblastoma: Clinical Outcome and Translational Analysis of a Single-Institution Phase I/II Trial

30. Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET

35. mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

36. Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging

38. Corrigendum: Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

39. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo

40. Erratum: Corrigendum: Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

41. AEE788

42. Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke

49. Long‐term protection of brain tissue from cerebral ischemia by peripherally administered peptidomimetic caspase inhibitors

Catalog

Books, media, physical & digital resources